The product designated as Calamine Lotion Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is a dry compendial mixture of zinc oxide and ferric oxide rather than a finished lotion. It is supplied in two controlled particle-size models: CLM-VG-API-200, with a target volume median particle size such that D90 ≤ 20 µm, and CLM-VG-API-325, with D90 ≤ 45 µm. The term “Lotion” remains from the historical compendial name for calamine; the material itself is a pink to reddish-brown powder, practically insoluble in water and ethanol, and soluble with effervescence in dilute mineral acids. Release specifications follow the current USP-NF Calamine monograph for identity, assay, loss on ignition, acid-insoluble matter, arsenic, and lead. The material is additionally controlled for particle size, bulk density, and microbial enumeration because it is intended for conversion into oral solid doses, sterile or non-sterile suspensions, feed premixes, and dry oral powders. Finished human calamine lotion is not interchangeable with this API; the lotion contains water, suspending agents, and preservatives and is not released for dry processing or sterile preparation. The API is manufactured under a quality system aligned with veterinary active-substance GMP expectations and is supplied with a certificate of analysis that includes the compendial tests plus grade-specific particle-size data.

How Does a Compendial Zinc Oxide–Ferric Oxide Mixture Behave Across Seven Veterinary Dosage Forms?

For tablets, capsules, powders, and granules, the functional performance depends on the acid-reactive nature of zinc oxide. Calamine does not dissolve at neutral pH; it releases zinc ions in acidic media such as 0.1 N HCl. Dissolution testing under USP <711> with an acid-stage medium is therefore more relevant than a purely aqueous buffer system. The ferric oxide fraction remains as a pink insoluble residue and may require filtration or acid digestion before zinc quantification by atomic absorption spectroscopy or inductively coupled plasma optical emission spectrometry. A 100 mg quantity of calamine with a ZnO assay of 100.0% contains approximately 80.3 mg elemental zinc, based on the zinc-to-zinc oxide molecular weight ratio of 0.8034. Lot-specific elemental zinc content should be recalculated from the release assay rather than assumed from the nominal label. For pelletized premixes and oral powders, the product is not a soluble zinc salt, and zinc migration into the feed matrix is particle-size dependent; homogeneity must be verified by lot analysis rather than inferred from moisture movement. The assay method for calamine is typically a complexometric titration after hydrochloric acid digestion, with the acid-insoluble fraction determined gravimetrically after boiling in dilute hydrochloric acid, filtration, and ignition. Arsenic and lead are controlled by current compendial limits, and the certificate of analysis may also include cadmium and mercury data under an accredited method when the receiving market requires it.

The release profile is standardized around the following methods and limits.

When Particle Size Distribution Shifts, the Compression Window Closes

Experience with production-scale rotary tablet presses indicates that calamine powders with a Carr index above 30% and a Hausner ratio above 1.35 become prone to weight variation when the press speed exceeds 30 rpm on 12 mm round tooling. The CLM-VG-API-200 grade is sufficiently fine for suspension work but may require dry granulation or slugging before tableting. Roller compaction at roll pressures of 5.0–7.0 MPa followed by screen milling through a 1.0 mm mesh produces granules that perform acceptably in hard-gelatin capsule filling at 60–80% target fill volume. Wet granulation in a high-shear granulator at impeller speeds of 200–300 rpm and chopper speeds of 1,500–2,500 rpm may be used with 1.0–3.0% w/w hypromellose or pregelatinized starch as a binder. The granulation endpoint should be controlled by impeller power draw or torque, not visual appearance, and final granule loss on drying should be held between 1.0% and 2.0% before compression. Drying above 2.5% residual moisture has been associated with sticking to steel punches and picking during extended runs. Because the ferric oxide fraction is harder than the zinc oxide fraction, high-volume tablet campaigns exceeding 500,000 units should include more frequent tooling inspection for punch-tip abrasion and die-wall scoring. For direct-fill oral powders, geometric dilution and a final blend uniformity test are required; an acceptance range of 90.0–110.0% of labeled zinc content with a relative standard deviation ≤ 5.0% is a useful in-house specification when the test method is validated. The powder should be protected from acidic binders during wet granulation because citric acid and similar agents can pre-react with zinc oxide, shifting the assay and altering granule hardness before compression.

The injectable and solution designations impose a separate constraint because calamine cannot form a molecular solution at physiological pH. A sterile injection can only be a suspension. Terminal sterilization by autoclaving at 121 °C for 15 min is feasible from a microbiological perspective, but the thermal load can increase particle settling and caking if the vehicle does not provide a yield stress. The high true density of calamine produces rapid Stokes-law sedimentation; terminal wet media milling with 0.3–0.5 mm zirconia beads to D90 ≤ 10 µm is generally necessary for injectable feasibility work. Such processing may introduce metallic wear residues and requires a validated cleaning and sieving step before sterilization. Published data for calamine-containing injectable veterinary products is limited. Parenteral administration of insoluble ferric oxide particles raises particulate-matter safety concerns; compliance with USP <788> subvisible particulate limits is required, and the formulation must demonstrate consistent resuspendability without aggregate sizes above the target range. If a true solution of zinc is required, zinc sulfate or zinc chloride is the appropriate API. Calamine is unsuitable where molecular zinc pharmacokinetics is the intended design. The term “Solutions” in the product designation must therefore be read as a liquid dosage form category that requires a suspending agent. Avoid combination with strong chelating agents such as disodium edetate in aqueous vehicles because chelation can leach zinc from the particle surface and alter free zinc concentration over shelf life. For injectable development, bacterial endotoxin testing according to Ph. Eur. 2.6.14 should be added to the API release and finished-product release protocols because the API is not supplied as a sterile or depyrogenated material.

Where Suspension Rheology Replaces Solubility Parameters

In oral and topical suspensions, calamine release and dose uniformity are governed by the finished suspension’s rheology rather than by dissolution alone. Flocculated systems prepared with xanthan gum, bentonite, or microcrystalline cellulose/carboxymethylcellulose co-processed excipients at 0.2–0.5% w/w provide a yield stress that reduces sedimentation while permitting resuspension by shaking. The zeta potential of dispersed zinc oxide approaches zero near pH 9–10, which can lead to particle aggregation. Addition of sodium lauryl sulfate at 0.05–0.1% w/w shifts the surface charge to more negative values and improves wetting; excessive surfactant causes foaming and may require vacuum deaeration. In production-scale high-shear dispersion, a rotor-stator mixer operated at 3,000–5,000 rpm for 10–15 min is usually sufficient to deagglomerate the API in a liquid vehicle. Longer mixing can reduce the viscosity of xanthan gum by localized heating and shear degradation. The insoluble ferric oxide marker remains visible as a pink particulate phase; this is an identification feature of the dosage form and must not be mistaken for incomplete dispersion.

For feed premix operations, the API is diluted with a carrier such as ground limestone or corn cob at ratios of 1:100 to 1:1,000. Ribbon blenders operated at 70% working capacity or less provide acceptable blend uniformity when the API D90 is smaller than the carrier particle size. Static charge buildup has been observed at relative humidity below 30% on production lines, causing adhesion to stainless steel walls and low assay in final premix samples. Preconditioning powder at 45–55% RH before mixing and grounding the blender reduce the effect. If the material is stored at relative humidity above 60%, tray drying at 105 °C to constant mass is recommended before dry processing to restore flow. The product should be stored in well-closed containers at 15–25 °C and protected from moisture and acidic vapors.

Feed-Grade Zinc Oxide, Zinc Oxide API, and Calamine API: Release Limits and Processing Divergence

Calamine veterinary API is distinguished from feed-grade zinc oxide by compendial identity, release testing, and controlled ferric oxide content. Feed-grade zinc oxide is not released under a pharmacopoeial monograph and can vary in lead, cadmium, and arsenic depending on ore source. Compendial zinc oxide API has a tighter ZnO assay window, typically 99.0–100.5%, and lacks the ferric oxide marker. It is appropriate when a white zinc source is required or when the marketing authorization lists zinc oxide as the active substance. If the authorization lists calamine, substitution with zinc oxide is not permitted without a variation, because the calamine monograph includes ferric oxide as part of the defined composition. The presence of ferric oxide can accelerate tablet tooling wear and may influence optical inspection systems that use color as an acceptance criterion.

The operational boundary is that this product is a dry API for further manufacture; it is not a finished dosage form and is not intended for direct administration without formulation and release testing. Batch-to-batch particle-size verification is required because the final milling step determines whether the material is suitable for direct compression, dry granulation, suspension, or premix use. Products using the same monograph identity but different particle-size distributions should not be substituted without requalification in the finished dosage form. When the receiving formulation includes a liquid vehicle, the API should be added under high-shear dispersion rather than assumed to dissolve, because calamine remains a suspended particulate system throughout the shelf life of the finished product.